Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

被引:252
作者
Hallek, Michael [1 ]
Al-Sawaf, Othman [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, Aachen Bonn Koln Dusseldorf, Ctr Integrated Oncol,Ctr Excellence Cellular Stre, Cologne, Germany
关键词
PREVIOUSLY UNTREATED PATIENTS; MINIMAL RESIDUAL DISEASE; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-III TRIAL; STEM-CELL TRANSPLANTATION; PROGRESSION-FREE SURVIVAL; MODIFIED T-CELLS; HIGH-RISK CLL; OPEN-LABEL; 1ST-LINE THERAPY;
D O I
10.1002/ajh.26367
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B-cells. Diagnosis The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen as well as typical B-cell markers. Prognosis and staging The clinical staging systems provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 (del[17p]) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. Therapy Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: a combination of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib, or chemoimmunotherapy. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del(17p) or TP53 mutation are usually resistant to chemotherapy and should, therefore, be treated with targeted agents. Future challenges Combinations of targeted agents are now being investigated to create efficient, potentially curative therapies of CLL with fixed duration. One of the most relevant questions currently addressed in clinical trials is the comparison of monotherapies with BTK inhibitors with fixed duration combination therapies. Moreover, the optimal sequencing of targeted therapies remains to be determined. Alternative therapies are needed for patients with BTK and BCL2 inhibitor double-refractory disease.
引用
收藏
页码:1679 / 1705
页数:27
相关论文
共 249 条
[1]   Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study [J].
Abdel-Qadir, Husam ;
Sabrie, Nasruddin ;
Leong, Darryl ;
Pang, Andrea ;
Austin, Peter C. ;
Prica, Anca ;
Nanthakumar, Kumaraswamy ;
Calvillo-Arguelles, Oscar ;
Lee, Douglas S. ;
Thavendiranathan, Paaladinesh .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) :3453-+
[2]   Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].
Advani, Ranjana H. ;
Buggy, Joseph J. ;
Sharman, Jeff P. ;
Smith, Sonali M. ;
Boyd, Thomas E. ;
Grant, Barbara ;
Kolibaba, Kathryn S. ;
Furman, Richard R. ;
Rodriguez, Sara ;
Chang, Betty Y. ;
Sukbuntherng, Juthamas ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Hedrick, Eric ;
Fowler, Nathan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94
[3]   Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model [J].
Ahn, Inhye E. ;
Tian, Xin ;
Ipe, David ;
Cheng, Mei ;
Albitar, Maher ;
Tsao, L. Claire ;
Zhang, Lei ;
Ma, Wanlong ;
Herman, Sarah E. M. ;
Gaglione, Erika M. ;
Soto, Susan ;
Dean, James P. ;
Wiestner, Adrian .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) :576-+
[4]   Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations [J].
Ahn, Inhye E. ;
Tian, Xin ;
Wiestner, Adrian .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (05) :498-500
[5]   Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia [J].
Ahn, Inhye E. ;
Underbayev, Chingiz ;
Albitar, Adam ;
Herman, Sarah E. M. ;
Tian, Xin ;
Maric, Irina ;
Arthur, Diane C. ;
Wake, Laura ;
Pittaluga, Stefania ;
Yuan, Constance M. ;
Stetler-Stevenson, Maryalice ;
Soto, Susan ;
Valdez, Janet ;
Nierman, Pia ;
Lotter, Jennifer ;
Xi, Liqiang ;
Raffeld, Mark ;
Farooqui, Mohammed ;
Albitar, Maher ;
Wiestner, Adrian .
BLOOD, 2017, 129 (11) :1469-1479
[6]  
Al-Sawaf O, 2020, LANCET ONCOL, V21, P1188, DOI 10.1016/S1470-2045(20)30443-5
[7]  
AlSawaf O., 2021, Hematological Oncology, V39, P64
[8]   Infections in patients with chronic lymphocytic leukemia treated with fludarabine [J].
Anaissie, EJ ;
Kontoyiannis, DP ;
O'Brien, S ;
Kantarjian, H ;
Robertson, L ;
Lerner, S ;
Keating, MJ .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) :559-566
[9]  
[Anonymous], 1999, J Natl Cancer Inst, V91, P861
[10]  
[Anonymous], 2021, Cancer Stat Facts: Leukemia